Annexon, Inc.

Annexon, Inc. is a biopharmaceutical company that develops targeted immunotherapies for complement-mediated neuroinflammatory diseases. These diseases affect nearly 10 million people globally. The company focuses on the classical complement pathway, a part of the body's immune system that triggers inflammation. Annexon aims to stop this pathway at its beginning by targeting C1q, its initiating molecule. This approach is intended to offer comprehensive protection against complement-mediated disorders affecting the body, brain, and eye. Using its proprietary platform, Annexon identifies and characterizes the classical complement pathway's role in three therapeutic areas: autoimmune diseases, neurodegeneration, and ophthalmology. The company is developing product candidates designed to block the early classical cascade and all subsequent pathway components and their tissue-damaging effects. The objective is to suppress excessive or abnormal classical complement activity that causes chronic inflammation and tissue damage, potentially slowing or halting disease progression. This is done while preserving the beneficial immune functions of the lectin and alternative complement pathways, which are involved in clearing pathogens and damaged cells. With over a decade of experience in addressing neuroinflammation, Annexon has shown strong target engagement in the body, brain, and eye, and has achieved clinical proof of concept in multiple diseases.